Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
6-Month Intensive Period (182 Days)	STARTED	Delamanid + OBR	341
6-Month Intensive Period (182 Days)	STARTED	Placebo + OBR	170
6-Month Intensive Period (182 Days)	Received at Least 1 Dose of Study Drug	Delamanid + OBR	341
6-Month Intensive Period (182 Days)	Received at Least 1 Dose of Study Drug	Placebo + OBR	170
6-Month Intensive Period (182 Days)	COMPLETED	Delamanid + OBR	322
6-Month Intensive Period (182 Days)	COMPLETED	Placebo + OBR	156
6-Month Intensive Period (182 Days)	NOT COMPLETED	Delamanid + OBR	19
6-Month Intensive Period (182 Days)	NOT COMPLETED	Placebo + OBR	14
Continuation Period	STARTED	Delamanid + OBR	322
Continuation Period	STARTED	Placebo + OBR	156
Continuation Period	COMPLETED	Delamanid + OBR	288
Continuation Period	COMPLETED	Placebo + OBR	142
Continuation Period	NOT COMPLETED	Delamanid + OBR	34
Continuation Period	NOT COMPLETED	Placebo + OBR	14

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01424670/flow